N-acetylglutamate (NAG) content was measured in homogenates of liver and small intestine obtained from normal and 24-h starved syngeneic mice. Subsequently, NAG was determined in normal, and in carbamyl phosphate synthetase I and ornithine transcarbamylase enzyme-deficient human liver tissue homogenates.
Clinical and investigative medicine. Medecine clinique et experimentale, 13(4), 183-188 (1990-08-01)
Liver tissue from 3 patients with carbamyl phosphate synthetase I deficiency and 11 patients with ornithine transcarbamylase deficiency was analyzed by Western blots for the presence of carbamyl phosphate synthetase I and ornithine transcarbamylase cross-reactive material with anti-rat enzyme antibodies.
Biochemical medicine and metabolic biology, 47(1), 38-46 (1992-02-01)
N-Acetyl-L-glutamate synthetase (NAG synthetase) is a mitochondrial matrix enzyme which catalyzes the synthesis of N-acetyl-Lglutamate (NAG), a physiologic activator of the urea cycle enzyme carbamylphosphate synthetase I. Deficiency of NAG synthetase in humans has been reported only three times previously.
Journal of chromatography. B, Biomedical applications, 657(1), 15-21 (1994-07-01)
Liquid chromatography-atmospheric pressure chemical-ionization mass spectrometry (LC-APCI-MS) was used for the analysis of N-acetylamino acids that could not be determined with an amino acid analyzer. LC-APCI-MS could directly detect the protonated molecular ions of various synthetic N-acetylamino acids, distinguishing N-acetylserine
The American journal of clinical nutrition, 86(3), 672-681 (2007-09-08)
Previous studies suggest that high plasma concentrations of carotenoids, retinol, or tocopherols may reduce the risk of prostate cancer. We aimed to examine the associations between plasma concentrations of 7 carotenoids, retinol, alpha-tocopherol, and gamma-tocopherol and prostate cancer risk. A